摘要
目的:探讨血必净联合乌司他丁在脓毒血症合并感染性休克患者中的应用价值。方法:选取2010年1月-2015年1月在笔者所在医院重症医学科确诊为脓毒血症合并感染性休克病例进行分析,共72例,将病例随机分为两组,每组36例。对照组采用常规治疗,研究组采用血必净联合乌司他丁治疗。研究组乌司他丁应用为20万U静滴,每8小时一次,联合血必净50 ml静滴,每12小时一次,连续应用7 d。观察两组炎症介质IL-6、TNF-α、PCT、CRP的变化,以及血管活性药物(多巴胺、去甲肾上腺素)的用量及应用时间、机械通气时间以及死亡率变化。结果:研究组炎症介质IL-6、TNF-α、PCT、CRP较对照组有明显低,血管活性药物(去甲肾上腺素)的用量及应用时间明显减少及缩短,机械通气时间少于对照组,死亡率低于对照组,差异有统计学意义(P<0.05)。结论:血必净联合乌司他丁应用能有效降低脓毒血症合并感染性休克患者的炎症反应,促进血流动力学稳定,降低患者死亡率,值得临床广泛推广。
Objective： To observe the clinical therapeutic efficiency of Ulinastatin combined with Xuebijing on sepsis with septic shock.Method： 72 patients from January 2010 to January 2015 on sepsis with septic shock were included and randomly divided into the control group and Xuebijing combined with Ulinastatin group（the study group）, with 36 cases in each group.The patients in the control group were treated according to the therapy guideline of severe sepsis with septic shock.The patients in the study group were received Xuebijing injection 50 ml intravenous drip every 12 hours a day and Ulinastatin 200 000 Units intravenous drip every 8 hours a day for 7days.Blood concentrations of TNF-α, IL-6, PCT, CRP were tested and compared.The application time of Norepinephrine, the amount of Norepinephrine, the time of mechanical ventilation and the mortality of the two groups were recorded and compared.Result： IL-6, TNF- α, PCT, CRP in the study group decreased significantly after the treatment.The application time of nnrepinephrine was significantly shorter than that in the control group.The amount of Norepinephrine was significantly less than that of the control group.The time of mechanical ventilation in the study group was shorter than that in the control group, mortality of the study group was lower than that of the control group（P〈0.05）.Conclusion： The treatment of Xuebijing combined with Ulinastatin significantly reduced inflammation, promoted the stability of hemodynamics, reduced mortality, and it is worthy for clinical promoting widely.
出处
《中外医学研究》
2015年第21期37-39,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
